Use of β-Blockers in Patients with an Implantable Cardioverter Defibrillator

被引:2
作者
LaPointe, Nancy M. Allen [1 ]
Stafford, Judith A.
Pappas, Paul A. [2 ]
Al-Khatib, Sana M. [1 ]
Anstrorn, Kevin J. [3 ]
机构
[1] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27705 USA
[2] INC Res, Raleigh, NC USA
[3] Duke Univ, Dept Biostat & Bioinformat, Duke Clin Res Inst, Durham, NC 27705 USA
基金
美国国家卫生研究院;
关键词
beta-blocker; implantable cardioverter defibrillator; sudden cardiac arrest; HEART-FAILURE; PROPHYLACTIC IMPLANTATION; THERAPY; SURVIVAL; TRIAL; PREVENTION; TACHYCARDIA; MANAGEMENT; INFARCTION; ADHERENCE;
D O I
10.1345/aph.1M140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Implantable cardioverter defibrillators (ICDs) are indicated for both primary and secondary prevention of sudden cardiac arrest. beta-Blockers are also indicated in most patients who have an indication for an ICD; however, their use in this population is not well described. Some clinicians may be unaware of the recommendation for beta-blockers in this population. OBJECTIVE: To explore beta-blocker use among ICD recipients. METHODS: Adults who received their first ICD at Duke Hospital between July 1999 and July 2004 for primary or secondary prevention of sudden cardiac arrest were identified. Using hospital data, beta-blocker use was determined at time of discharge, and characteristics of users were compared with those of nonusers. Continued use of beta-blockers after ICD implant was explored in the subset of patients included in the Duke Databank for Cardiovascular Disease (DDCD). RESULTS: The study cohort comprised 804 patients, 652 (81%) with ICD for secondary prevention of sudden cardiac arrest and 152 (19%) for primary prevention. The median age was 65 years and 75% of the patients were men. A total of 544 (68%) received a beta-blocker at time of ICD implant. There were no substantial changes in the proportion of patients with beta-blocker use from 1999 through 2004, overall or within the primary or secondary prevention groups. However, beta-blocker use was higher in the secondary prevention group than in the primary prevention group (69% vs 60%; p = 0.02). A higher proportion of beta-blocker users versus nonusers had ischemic heart disease (82% vs 68%; p < 0.0001), heart failure (84% vs 71%; p < 0.0001), previous myocardial infraction (51% vs 44%; p = 0.05), and ventricular arrhythmias (82% vs 76%; p = 0.04). Of the 425 patients included in the DDCD, only 241 (57%) were receiving beta-blockers at time of implant and during clinical follow-up. CONCLUSIONS: Lower than optimal use of beta-blockers suggests the need for new methods of including evidence-based medications in clinical practice, especially for complex patients for whom numerous clinical practice guidelines may apply.
引用
收藏
页码:1189 / 1196
页数:8
相关论文
共 26 条
[1]   ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary [J].
Anderson, Jeffrey L. ;
Adams, Cynthia D. ;
Antman, Elliott M. ;
Bridges, Charles R. ;
Califf, Robert M. ;
Casey, Donald E., Jr. ;
Chavey, William E., II ;
Fesmire, Francis M. ;
Hochman, Judith S. ;
Levin, Thomas N. ;
Lincoff, A. Michael ;
Peterson, Eric D. ;
Theroux, Pierre ;
Wenger, Nanette Kass ;
Wright, R. Scott ;
Smith, Sidney C., Jr. ;
Jacobs, Alice K. ;
Adams, Cynthia D. ;
Riegel, Barbara .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :652-726
[2]  
Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014
[3]  
Bardy GH, 2005, NEW ENGL J MED, V352, P2146
[4]  
Bonow RO, 2008, J AM COLL CARDIOL, V52, pE1, DOI [10.1016/j.jacc.2008.05.007, 10.1016/j.hrthm.2008.04.014]
[5]   Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II) [J].
Brodine, WN ;
Tung, RT ;
Lee, JK ;
Hockstad, ES ;
Moss, AJ ;
Zareba, W ;
Hall, WJ ;
Andrews, M ;
McNitt, S ;
Daubert, JP .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (05) :691-695
[6]   Outpatient adherence to beta-blocker therapy after acute myocardial infarction [J].
Butler, J ;
Arbogast, PG ;
BeLue, R ;
Daugherty, J ;
Jain, MK ;
Ray, WA ;
Griffin, MR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (09) :1589-1595
[7]   A randomized study of the prevention of sudden death in patients with coronary artery disease [J].
Buxton, AE ;
Lee, KL ;
Fisher, JD ;
Josephson, ME ;
Prystowsky, EN ;
Hafley, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1882-1890
[8]   Effect of β-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT) [J].
Ellison, KE ;
Hafley, GE ;
Hickey, K ;
Kellen, J ;
Coromilas, J ;
Stein, KM ;
Lee, KL ;
Buxton, AE .
CIRCULATION, 2002, 106 (21) :2694-2699
[9]   Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: The Antiarrhythmics Versus Implantable Defibrillators (AVID) trial [J].
Exner, DV ;
Reiffel, JA ;
Epstein, AE ;
Ledingham, R ;
Reiter, MJ ;
Yao, Q ;
Duff, HJ ;
Follmann, D ;
Schron, E ;
Greene, HL ;
Carlson, MD ;
Brodsky, MA ;
Akiyama, T ;
Baessler, C ;
Anderson, JL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (02) :325-333
[10]   2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina [J].
Fraker, Theodore D. ;
Fihn, Stephan D. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (23) :2264-2274